Michael Thomas Heffernan
CIK: 0001448914
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Exercise(M)Direct21.1K shares at avg. $3.33$70K - Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Sale(S)Direct18.3K shares at avg. $15.09$276K - Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Sale(S)Direct100 shares at avg. $15.88$2K - Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Exercise(M)Direct18.4K shares at avg. $3.04$56K - Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Sale(S)Direct21K shares at avg. $15.09$316K - Sep 15, 2026TRVI
Trevi Therapeutics, Inc.
Sale(S)Direct100 shares at avg. $15.88$2K - Jun 16, 2026ENGN
enGene Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares- - Jun 3, 2026TRVI
Trevi Therapeutics, Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
35K shares- - Jun 2, 2026AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
29.5K shares- - Apr 28, 2026BHVN
Biohaven Ltd.
Award(A)DirectStock Options (Right to buy)
68.7K shares- - Jul 8, 2025ENGN
enGene Holdings Inc.
Award(A)DirectStock Option (Right to Buy)
45K shares- - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
29.5K shares- - Jun 11, 2025TRVI
Trevi Therapeutics, Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
45K shares- - May 5, 2025BHVN
Biohaven Ltd.
Award(A)DirectStock Options (Right to buy)
31.7K shares- - Mar 25, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
50K shares- - Feb 10, 2025COLL
COLLEGIUM PHARMACEUTICAL, INC
Award(A)Direct4.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 |  TRVI Trevi Therapeutics, Inc. | Exercise(M) | 21,052 | $3.33 | $70,103 | Direct |
| Sep 15, 2026 | TRVI Trevi Therapeutics, Inc. | Sale(S) | 18,321 | $15.09 | $276,464 | Direct |
| Sep 15, 2026 | TRVI Trevi Therapeutics, Inc. | Sale(S) | 100 | $15.88 | $1,588 | Direct |
| Sep 15, 2026 | TRVI Trevi Therapeutics, Inc. | Exercise(M) | 18,421 | $3.04 | $56,000 | Direct |
| Sep 15, 2026 | TRVI Trevi Therapeutics, Inc. | Sale(S) | 20,952 | $15.09 | $316,166 | Direct |
| Sep 15, 2026 | TRVI Trevi Therapeutics, Inc. | Sale(S) | 100 | $15.88 | $1,588 | Direct |
| Jun 16, 2026 |  ENGN enGene Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
| Jun 3, 2026 | TRVI Trevi Therapeutics, Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 35,000 | - | - | Direct |
| Jun 2, 2026 |  AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 29,500 | - | - | Direct |
| Apr 28, 2026 |  BHVN Biohaven Ltd. | Award(A) Stock Options (Right to buy) | 68,693 | - | - | Direct |
| Jul 8, 2025 | ENGN enGene Holdings Inc. | Award(A) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 29,500 | - | - | Direct |
| Jun 11, 2025 | TRVI Trevi Therapeutics, Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 45,000 | - | - | Direct |
| May 5, 2025 | BHVN Biohaven Ltd. | Award(A) Stock Options (Right to buy) | 31,716 | - | - | Direct |
| Mar 25, 2025 | AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Feb 10, 2025 |  COLL COLLEGIUM PHARMACEUTICAL, INC | Award(A) | 4,820 | - | - | Direct |
1-16 of 16 transactions
About Heffernan Michael Thomas
Heffernan Michael Thomas (SEC CIK 0001448914) files insider reports with the SEC as Director of Trevi Therapeutics, Inc. (TRVI), Director of enGene Therapeutics Inc. (ENGN) and Director of Avalo Therapeutics, Inc. (AVTX). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 13 ownership filings by Heffernan Michael Thomas (2 Form 3, 11 Form 4), filed between Feb 12, 2025 and Sep 17, 2026. Those filings report 16 transactions, from Feb 10, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Heffernan Michael Thomas's filings is in NEW HAVEN, CT.
Recent filings by Heffernan Michael Thomas
- Sep 15, 2026: Option exercise of TRVI shares (Form 4, code M).
- Sep 15, 2026: Open-market sales of TRVI shares (2 lines, Form 4, code S).
- Sep 15, 2026: Option exercise of TRVI shares (Form 4, code M).
- Sep 15, 2026: Open-market sales of TRVI shares (2 lines, Form 4, code S).
- Jun 16, 2026: Grant or award of ENGN derivative securities (Form 4, code A).
Other insiders filing for Trevi Therapeutics, Inc. (TRVI)
- Mathers Edward T, Director
- Colangelo Dominick, Director
- Meeker David P, Director
- VANLENT ANNE, Director
- Cassella James V, Chief Development Officer
- Galletta Christopher